Menu Search
Equities

Marksans Pharma Ltd

MARKSANS:NSI

Marksans Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)308.65
  • Today's Change0.25 / 0.08%
  • Shares traded2.95m
  • 1 Year change+120.94%
  • Beta1.2965
Data delayed at least 15 minutes, as of Nov 22 2024 10:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 2 analysts offering 12 month price targets for Marksans Pharma Ltd have a median target of 307.50, with a high estimate of 350.00 and a low estimate of 265.00. The median estimate represents a -0.16% decrease from the last price of 308.00.
High13.6%350.00
Med-0.2%307.50
Low-14.0%265.00

Dividends

In 2024, Marksans Pharma Ltd reported a dividend of 0.60 INR, which represents a 20.00% increase over last year. The analyst covering the company expects dividends of 0.70 INR for the upcoming fiscal year, an increase of 16.67%.
Div growth (TTM)20.00%
More ▼

Earnings history & estimates in INR

Marksans Pharma Ltd reported annual 2023 earnings of 6.41 per share on May 30, 2023.
Average growth rate+222.06%
More ▼

Revenue history & estimates in INR

Marksans Pharma Limited had 2nd quarter 2025 revenues of 6.42bn. This bettered the 6.28bn estimate of the one analyst covering the company. The same period last year the company did not report revenues.
Average growth rate+10.93%
Marksans Pharma Limited had revenues for the full year 2024 of 21.77bn. This was 17.56% above the prior year's results.
Average growth rate+17.87%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.